Lotus Tissue Repair has secured $26 million in a Series A financing round, allowing it to launch as a spinoff of Third Rock Ventures. The startup will use the money to develop a proprietary recombinant collagen type VII technology into a collagen-based treatment for dystrophic epidermolysis bullosa, a rare skin disease. The University of Southern California licensed the technology to Lotus.

Related Summaries